The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.
including lenalidomide and a proteasome inhibitor. The approval covers Sarclisa's use in combination with pomalidomide and dexamethasone (Pd). Regulators in China endorsed the drug based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback